NVO USThe decline in Novo Nordisk shares is not the result of a single factor, but rather the result of a complex set of fundamental issues: weakening financial performance, loss of competitive advantage in key products, and increased strategic risks.
While negative data on Eli Lilly's weight loss pill i
Novo Nordisk A/S Sponsored ADR Class B
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.47 USD
15.49 B USD
46.74 B USD
3.37 B
About Novo Nordisk A/S Class B
Sector
Industry
CEO
Maziar Mike Doustdar
Website
Headquarters
Bagsværd
Founded
1923
IPO date
May 17, 1974
Identifiers
3
ISIN US6701002056
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS323295972
Novo Nordisk Finance (Netherlands) BV 4.0% 20-NOV-2045Yield to maturity
4.27%
Maturity date
Nov 20, 2045
N
XS323295590
Novo Nordisk Finance (Netherlands) BV 3.625% 20-FEB-2038Yield to maturity
3.75%
Maturity date
Feb 20, 2038
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037Yield to maturity
3.74%
Maturity date
May 27, 2037
N
XS323294453
Novo Nordisk Finance (Netherlands) BV 3.375% 20-FEB-2035Yield to maturity
3.51%
Maturity date
Feb 20, 2035
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034Yield to maturity
3.40%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033Yield to maturity
3.21%
Maturity date
May 27, 2033
N
XS323293716
Novo Nordisk Finance (Netherlands) BV 3.0% 20-FEB-2032Yield to maturity
3.10%
Maturity date
Feb 20, 2032
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030Yield to maturity
2.92%
Maturity date
Aug 27, 2030
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031Yield to maturity
2.91%
Maturity date
Jan 21, 2031
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030Yield to maturity
2.70%
Maturity date
Mar 31, 2030
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028Yield to maturity
2.62%
Maturity date
May 27, 2028
See all NVO bonds
XMEM
Xtrackers MSCI Emerging Markets Swap UCITS ETF Capitalisation 1CWeight
1.78%
Market value
18.24 M
USD
Explore more ETFs

